TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35325846
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% lidocaine with paracetamol
Study: 35325846
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% lidocaine with ibuprofen
Study: 35325846
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol alone
Study: 32565458
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen alone
Study: 32474062
Drug: Immediate restart
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immediate restart of COC after taking UPA 30 mg
Study: 32474062
Drug: Delayed restart
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Delayed restart of COC after taking UPA 30 mg
Study: 33191835
Drug: Cyclosporine administered
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine administered by continuous intravenous infusion for 5 days in a novel Cremophor/Kolliphor EL-free lipid emulsion, NeuroSTAT
Study: 33965603
Drug: CAL-DL-PDT (calcitriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAL-DL-PDT (calcitriol followed by methyl aminolevulinate daylight photodynamic therapy)
Study: 33965603
Drug: P-DL-PDT (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-DL-PDT (placebo followed by methyl aminolevulinate daylight photodynamic therapy)
Study: 33653982
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with 40 ml of ropivacaine 0.5% at T9 level bilaterally
Study: 32495449
Drug: Remimazolam (RMZ)
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam (RMZ) 5 mg and 10 mg
Study: 32495449
Drug: Midazolam (MDZ)
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (MDZ) 2.5 mg and 5 mg
Study: 35766126
Drug: Intravenous Regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Regional Anesthesia (IVRA)
Study: 34081113
Drug: HMB (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB (1500 mg daily)
Study: 32654242
Drug: Maca (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maca (2 g/day for 12 weeks)
Study: 32654242
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 g/day for 12 weeks)
Study: 36163944
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (n=18) in PRINCE study
Study: 35940836
Drug: Intravenous beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous beta-blocker administration
Study: 34738474
Drug: Music-guided exercise
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music-guided exercise intervention (n = 13), individualized music playlist, twice daily for 5 days.
Study: 33891379
Drug: Bimekizumab (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab (320 mg every 4 weeks for 56 weeks)
Study: 33891379
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg every 2 weeks for 24 weeks, then bimekizumab every 4 weeks to week 56)
Study: 33011968
Drug: Dual triggering
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual triggering with 10,000 units of hCG plus 0.2 mg of triptorelin
Study: 34454260
Drug: Tapentadol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol (50 mg)
Study: 34358344
Drug: FC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FC plus low-dose oxytocin
Study: 33872652
Drug: Astegolimab 490
Normalized name: Astegolimab
DrugBank: Astegolimab (DB16386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astegolimab 490 mg
Study: 33872652
Drug: Astegolimab 210
Normalized name: Astegolimab
DrugBank: Astegolimab (DB16386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astegolimab 210 mg
Study: 33872652
Drug: Astegolimab 70
Normalized name: Astegolimab
DrugBank: Astegolimab (DB16386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astegolimab 70 mg
Study: 33872652
Drug: Astegolimab 490
Normalized name: Astegolimab
DrugBank: Astegolimab (DB16386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astegolimab 490 mg (eosinophil-low)
Study: 33872652
Drug: Astegolimab 210
Normalized name: Astegolimab
DrugBank: Astegolimab (DB16386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astegolimab 210 mg (eosinophil-low)
Study: 33872652
Drug: Astegolimab 70
Normalized name: Astegolimab
DrugBank: Astegolimab (DB16386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astegolimab 70 mg (eosinophil-low)
Study: 35363301
Drug: Samotolisib (LY3023414)
Normalized name: Samotolisib
DrugBank: LY-3023414 (DB12167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samotolisib (LY3023414) 200 mg twice daily plus enzalutamide 160 mg daily
Study: 35363301
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus enzalutamide 160 mg daily
Study: 33149022
Drug: Percutaneous tibial
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous tibial nerve stimulation plus medical treatment (arm A)
Study: 33149022
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (arm B)
Study: 36153028
Drug: Early Adolescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early Adolescent Skills for Emotions (EASE) intervention, delivered in 7-weekly adolescent sessions and 3-biweekly caregiver sessions.
Study: 32277824
Drug: upadacitinib 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib 7.5 mg
Study: 33625673
Drug: Hydroxamate-based HDAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxamate-based HDAC inhibitors using receptor-dependent 4D-QSAR model
Study: 33977947
Drug: 2S‐hesperidin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2S‐hesperidin (500 mg d‐1)
Study: 33977947
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg d‐1 microcellulose)
Study: 35236646
Drug: Butylphthalide treatment
Normalized name: Butylphthalide
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butylphthalide treatment
Study: 33289028
Drug: Core Elements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core Elements of Outpatient Antibiotic Stewardship implementation
Study: 32621263
Drug: Life Review
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life Review Therapy and Memory Specificity Training (LRT‐MST)
Study: 33082178
Drug: Tailored letter
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tailored letter incorporating patient's screening test results and treatment algorithms sent to family physician
Study: 32616329
Drug: DAPT with
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT with clopidogrel and aspirin
Study: 34383540
Drug: Metacognitive interpersonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive interpersonal therapy-group (MIT-G)
Study: 34383540
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) + waiting list
Study: 32990231
Drug: Straumann implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Straumann implant
Study: 32959223
Drug: Ceratonia siliqua
Normalized name: CERATONIA SILIQUA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceratonia siliqua (carob) syrup twice a day for 3 months
Study: 32959223
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 100 mg twice a day for 3 months
Study: 32943404
Drug: Methylprednisolone pulse
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone pulse (intravenous injection, 250 mg·day‐1 for 3 days)
Study: 33473021
Drug: Parenteral iron
Normalized name: Iron, parenteral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral iron dextran
Study: 614284972
Drug: Smartphone application-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone application-delivered notched music therapy and Ginkgo biloba for 3 months
Study: 32956506
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A (20 ml 2% lidocaine + 10 ml 8.4% sodium bicarbonate)
Study: 32956506
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B (20 ml 2% lidocaine + 10 ml 0.9% saline solution)
Study: 36089595
Drug: diacerein (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: diacerein (50mg twice daily)
Study: 32579779
Drug: Preoperative ultrasound
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative ultrasound guided parasternal block with 0.25% bupivacaine (4 mL into anterior intercostal spaces)
Study: 32579779
Drug: Postoperative parasternal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative parasternal intercostal block with 0.25% bupivacaine (4 mL into anterior intercostal spaces)
Study: 35760338
Drug: CPT‐SMART (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐SMART (Cognitive Processing Therapy for PTSD, smoking cessation counseling, pharmacotherapy, and contingency management)
Study: 35598084
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.2% Ropivacaine with dexamethasone 8 mg (Group R + D)
Study: 35598084
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.2% Ropivacaine (Group R)
Study: 33721441
Drug: Nimotuzumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab + PF induction chemotherapy (NPF group)
Study: 33721441
Drug: TPF induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF induction chemotherapy (TPF group)
Study: 33727509
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patch (10 mg over 24 h, with a second patch after 1 h if contractions persisted)
Study: 33727509
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (20 mg loading dose, followed by 10 mg thrice daily if contractions suppressed)
Study: 33727509
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patch
Study: 35662230
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy (not specified dosage or duration)
Study: 33120078
Drug: Compound 34
Normalized name: Enflurane 99.9% Inhalation Solution [COMPOUND 347]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound 34 (naphthyridinone scaffold)
Study: 32138765
Drug: Vitamin D/calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D/calcium milk fortification and periodontal therapy
Study: 35649707
Drug: HEAVY (high-load
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEAVY (high-load strengthening exercise, supervised twice/week)
Study: 34608631
Drug: Efgartigimod 10
Normalized name: Efgartigimod alfa
DrugBank: Efgartigimod alfa (DB15270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Efgartigimod 10 mg/kg
Study: 33249347
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group received constant TENS over the hamstring muscles during exercises.
Study: 35219521
Drug: High tidal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tidal volume (HTV) ventilation (>10 mL/kg predicted body weight)
Study: 35219521
Drug: Non-high tidal
Normalized name: marine non-gelling gelatin, high MW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-high tidal volume (non-HTV) ventilation (≤10 mL/kg predicted body weight)
Study: 37026551
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg/d
Study: 32228343
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 500 mg/day for 6 months after LSG
Study: 32228343
Drug: No UDCA
Normalized name: ,no-udca
DrugBank: NCX-1000 (DB16026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No UDCA treatment (pre-2015 protocol)
Study: 33790084
Drug: Drug-containing foam
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-containing foam formulations (benzydamine, dexamethasone, allopurinol, rebamipide) prepared with 1–4% SM‐4
Study: 33269838
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 'kidney three-needle' therapy and fire needling therapy
Study: 32651141
Drug: 0.75 g
Normalized name: Allantoin 0.75 g in 75 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 g ZM in 10 mL oxymel
Study: 32651141
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g ZM in 10 mL oxymel
Study: 32651141
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of oxymel
Study: 35365594
Drug: MK-7 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-7 (200 mcg/day)
Study: 33974018
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy (co-trimoxazole or doxycycline)
Study: 34029448
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose (HD) glucagon infusion (25 ng/kg/min)
Study: 34029448
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose (LD) glucagon infusion (12.5 ng/kg/min)
Study: 33144331
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg [14C]lemborexant (100 µCi)
Study: 34092191
Drug: Beta-alanine (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (6.4 g·day‐1 for 28 days)
Study: 34868479
Drug: Unguided online
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguided online cognitive-behavioral therapy (CBT)
Study: 34868479
Drug: Guided online
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided online cognitive-behavioral therapy (CBT)
Study: 33528893
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg/day for 13 weeks
Study: 35457330
Drug: L-arginine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (8 gr daily for 8 days)
Study: 35457330
Drug: L-citrulline (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline (8 gr daily for 8 days)
Study: 35457330
Drug: Placebo (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (8 gr daily for 8 days)
Study: 35457330
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (L-arginine, L-citrulline, and placebo)
Study: 32320566
Drug: Control (investigator's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (investigator's choice of therapy)
Study: 33942343
Drug: Single-injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection of 10 mg nalbuphine
Study: 33942343
Drug: PCA-mimic method
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA-mimic method of 10 mg nalbuphine (2 mg once for five times with a 30-min interval)
Study: 34504336
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (500 ml)
Study: 36167537
Drug: Incremental hemodialysis
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incremental hemodialysis (twice-weekly for 6 weeks followed by thrice-weekly)
Study: 36167537
Drug: Conventional hemodialysis
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional hemodialysis (thrice-weekly)
Study: 34256795
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor rehabilitation (1 pre-rehabilitation session and 9 to 12 sessions including patient education, pelvic floor muscle exercises, pelvic floor electromyography biofeedback, and capacitive and sensory rectal training with a balloon probe)
Study: 33468271
Drug: Freeze-dried strawberry
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried strawberry (24 g/d for 90 days)
Study: 32428636
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy
Study: 35709650
Drug: Metformin Glycinate
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metformin Glycinate (MG) treatment
Study: 34256828
Drug: Decision support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision support intervention (DESI) for primary endocrine therapy (PET) or surgery with adjuvant therapies
Study: 34256828
Drug: Decision support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision support intervention (DESI) for adjuvant chemotherapy after surgery
Study: 35894958
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 3 mg/kg body mass
Study: 36350066
Drug: Phone-delivered CBT
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phone-delivered CBT (6, 8, or 12 weekly sessions) augmented with a CBT skills practice smartphone application
Study: 36350066
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) T2DM care
Study: 34997360
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + thermosensitive gel containing 0.8% oligo hyaluronic acid and octenidine HCl 0.625%
Study: 35975643
Drug: 0.247% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.247% ropivacaine in 20 mL for ACB and IPACK block
Study: 33511604
Drug: Standard emergency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard emergency room treatment
Study: 33511604
Drug: Standard ambulance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ambulance and hospital treatment
Study: 33367229
Drug: DMPA administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DMPA administration in the 12-14 mm group
Study: 33367229
Drug: DMPA administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DMPA administration in the 15-17 mm group
Study: 33367229
Drug: DMPA administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DMPA administration in the ≥ 18 mm group
Study: 33367229
Drug: 24-h MPA
Normalized name: MPA
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-h MPA concentrations post-DMPA administration
Study: 35759476
Drug: Enhanced cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced cognitive behavioural therapy (CBT) plus social participation program
Study: 32567233
Drug: Oxycodone combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone combined with flurbiprofen axetil (OF)
Study: 36073583
Drug: Complex therapy
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex therapy (standard treatment + cell therapy)
Study: 36073583
Drug: Endoscopic surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic surgical treatment
Study: 34910859
Drug: NVX‐CoV2373 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVX‐CoV2373 vaccine
Study: 32366273
Drug: CTTS monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CTTS monthly calls
Study: 33165918
Drug: Atropine 0.5
Normalized name: homatropine 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.5 mg (Group A)
Study: 35103539
Drug: Sorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib plus 3cir‐OFF HAIC (400 mg sorafenib twice daily + 35 mg/m2 oxaliplatin followed by 600 mg/m2 5‐fluorouracil, days 1‐3)
Study: 35103539
Drug: Sorafenib alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib alone (400 mg twice daily)
Study: 34563982
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose aspirin (LDA) 60 mg
Study: 33338437
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg every other day for 12 weeks
Study: 36450449
Drug: Tumour necrosis
Normalized name: Tumour necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumour necrosis factor (TNF) inhibitor (TNFi)
Study: 38915065
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (sulfasalazine and hydroxychloroquine)
Study: 36450449
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (TNFi and triple therapy)
Study: 34314856
Drug: MTM +
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MTM + 12 months of telehealth‐delivered medical nutrition therapy (tele‐MNT)